Abstract #2859
Development of a mucin4-targeting SPIO contrast agent for effective detection of pancreatic tumor cells in vitro and in vivo
Yun-Ming Wang 1 , Shou-Cheng Wu 1 , Chia-Yun Chen 2 , Gin-Chung Liu 2 , and Yu-Jen Chen 1
1
Department of Biological Science and
Technology, National Chiao Tung University, HsinChu,
Taiwan,
2
Department
of Medical Imaging, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan
In search of a unique and reliable contrast agent
targeting pancreatic adenocarcinoma, new multifunctional
nanoparticles (MnMEIO-silane-NH2-(MUC4)-mPEG NPs) were
successfully developed in this study. Mucin4-expression
levels were determined through different imaging studies
in a panel of pancreatic tumor cells (HPAC, BxPC-3, and
Panc-1) both in vitro and in vivo studies. The in vitro
T2-weighted MR imaging study in HPAC and Panc-1 tumor
cells treated with NPs showed - 89.1 5.7% and - 0.9
0.2% contrast enhancement whereas in in vivo study,
it is found to be - 81.5 4.5% versus - 19.6 5.2%
(post-injection) respectively.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
